A: None of the four compounds GHRP-2, GHRP-6, hexarelin, or ipamorelin are currently FDA-approved for any therapeutic indication
Nevertheless, in a systematic review and network meta-analysis of controlled studies reporting the risk of all-cause mortality, CV mortality, or myocardial infarction (MI), later-generation SUs such as glimepiride and gliclazide were associated with a significantly lower risk of all-cause and CV mortality compared to glibenclamide [59], whereas glibenclamide was associated with a lower risk of sudden cardiac arrest and ventricular arrhythmias, at least when compared to glipizide, and may be associated with a reduced risk of ventricular tachycardia and isolated ventricular premature complexes [60]
PanJWTelangFWLeeJHde GraafRARothmanDLSteinDTet al
Vitamin D supplementation for the prevention of total cancer incidence and mortality: An updated systematic review and meta-analysis
The concentrations of the remaining SCFAs and the BAs were determined through single-point calibration using the IS closest in retention time
Br J Urol 1994;74(2):210213